F8 and hemophilia A: The safety and efficacy of emicizumab has been demonstrated in adult and pediatric hemophilia A populations with and without FVIII inhibitors in the HAVEN clinical trial program [[9], [10], [11], [12], [13], [14]] and in real-world studies [[15], [16], [17], [18], [19], [20]].